viewSkinBioTherapeutics PLC

SkinBioTherapeutics continues workings on its partnerships


  • Spun out from OptiBiotix in 2017
  • Harnesses good bacteria to improve and support skin
  • Partnerships with Croda and Winclove
woman's face

Quick facts: SkinBioTherapeutics PLC

Price: 16.375 GBX

Market: AIM
Market Cap: £25.53 m

I can see everybody having a place for [SkinBiotix-based products] in their daily regime in one shape or another. Why would you not use something that is clinically proven to make you either look or feel better?

Stuart Ashman, chief executive


What it does

The clue is in the name: SkinBioTherapeutics PLC (LON:SBTX) is a Manchester-based life sciences company focused on skin health.

It was spun out from OptiBiotix Health PLC (LON:OPTI) a couple of years ago, and Opti remains the majority shareholder.

SkinBio’s SkinBiotix platform uses lysates (extracts) of probiotic bacteria – the ‘good’ bacteria – and has been shown to improve the barrier effect of skin models, improve repair and reduce bacterial load.

Think of SkinBiotix as the skincare equivalent of Intel or GoreTex: eventually, SkinBio wants to license out the technology so it becomes a key ingredient in products such as skin cream, or tablets or food supplements.

The AIM-listed company is exploring five avenues of development: medical biotics; pharmabiotics; access biotics; cosmetics; and cleanbiotics.


How it is doing

In July, the firm said Sederma, its partner in the cosmetics programme and a division of Croda International PLC (LON:CRDA), successfully replicated the lysate manufacturing process and achieved the same performance from the company’s SkinBiotix technology so it focused on validating a scale-up of the manufacturing process. The project was not impacted by the pandemic.

Meanwhile, regarding the collaboration with Winclove Probiotics on the development of a food supplement for patients with psoriasis, participants were invited to participate in a human study in which they will be provided with samples of AxisBiotix Ps to self-administer over eight weeks and track the impact of the food supplement on their skin condition. They will then submit their findings periodically through a bespoke mobile app, avoiding the need for clinical attendance.


What the boss says: Stuart Ashman, chief executive

"We have seen significant positive progress made on the first of our commercial programmes in recent weeks. In such an important scientific milestone, it is reassuring and provides validation of our approach that Sederma has been able to replicate the activity of the SkinBiotix technology and is pushing ahead with the next steps of the project.”

"In addition, establishing a clear pathway to commencing a food supplement trial to manage symptoms associated with psoriasis is a great step forward for our collaboration with Winclove. The progress made in such a short period of time is testament to the combined efforts of the SkinBioTherapeutics and Winclove team."




Inflexion points 

  • More commercial deals for Skinbiotix
  • Revenue momentum continues to build
  • Deals for MediBiotix in medical device applications and CleanBioti




The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...



SkinBioTherapeutics raise £4m to expand SkinBiotix technology in oral and...

Skinbiotherapeutics Plc's (LON:SBTX) Doug Quinn talks to Proactive's Katie Pilbeam on their plans for the £4m raised from existing and new institutions to fund work on new product applications. Quinn explains how they plan to expand skin biotics technology into oral and healthcare as...

on 14/10/20

3 min read